NASDAQ:TPST

Tempest Therapeutics Stock Insider Trading

etoro logo Buy TPST
*Your capital is at risk
$0.86
-0.0074 (-0.86%)
At Close: Jul 31, 2026

Tempest Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 98.67. In total, the insiders bought 8.44M and sold 1.58M TPST shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 100 transactions)
98.67
Buy 8.44M shares
Sell 1.58M shares
96% Buy Activity
Strong Negative Correlation
Buy Signal High Confidence
Mar 24, 2026

Analysis Breakdown:

  • Strongly supported by a very high Insider Power Score of 98.67.
  • Confidence increased due to high data reliability score of 90.
  • Supported by overwhelming buy-side pressure (96% buys).

Historical Insider Trades

Date Type Person Role Amount
Oct 03, 2022
Buy
Employee Stock Option (right to buy)
A-Award
Trojanowski Justin
Corporate Controller
Officer 2 500
Value: $0
Oct 03, 2022
Buy
Employee Stock Option (right to buy)
A-Award
Trojanowski Justin
Corporate Controller
Officer 2 500
Value: $0
Sep 30, 2022
Buy
Employee Stock Option (right to buy)
Trojanowski Justin
Corporate Controller
Officer 10 000
Value: $22.9K
Sep 30, 2022
Buy
Employee Stock Option (right to buy)
Trojanowski Justin
Corporate Controller
Officer 10 000
Value: $22.9K
Jun 22, 2022
Buy
Stock Option (Right to Buy)
A-Award
Whiting Samuel
Chief Medical Officer
Officer 55 680
Value: $0
Jun 22, 2022
Buy
Stock Option (Right to Buy)
A-Award
Whiting Samuel
Chief Medical Officer
Officer 55 680
Value: $0
Jun 21, 2022
Buy
Stock Option (Right to Buy)
A-Award
Lorenzo Pierre
Corporate Controller
Officer 8 477
Value: $0
Jun 21, 2022
Buy
Stock Option (Right to Buy)
A-Award
Maestas Nicholas
Vp Of Strategy And Finance
Officer 51 270
Value: $0
Jun 21, 2022
Buy
Stock Option (Right to Buy)
A-Award
Dubensky Thomas W.
President
CEO / President 87 801
Value: $0
Jun 21, 2022
Buy
Stock Option (Right to Buy)
A-Award
Dubensky Thomas W.
President
CEO / President 87 801
Value: $206.3K
Jun 21, 2022
Buy
Stock Option (Right to Buy)
A-Award
Brady Stephen R
Chief Executive Officer
CEO / President 173 533
Value: $0
Jun 21, 2022
Buy
Stock Option (Right to Buy)
A-Award
Dubensky Thomas W.
President
CEO / President 87 801
Value: $206.3K
Jun 21, 2022
Buy
Stock Option (Right to Buy)
A-Award
Dubensky Thomas W.
President
CEO / President 87 801
Value: $0
Jun 21, 2022
Buy
Stock Option (Right to Buy)
A-Award
Maestas Nicholas
Vp Of Strategy And Finance
Officer 51 270
Value: $0
Jun 17, 2022
Buy
Stock Option (Right to Buy)
A-Award
Woiwode Thomas
Director 3 500
Value: $0
Jun 17, 2022
Buy
Stock Option (Right to Buy)
A-Award
Woiwode Thomas
Director
Director 3 500
Value: $7K
Jun 17, 2022
Buy
Stock Option (Right to Buy)
A-Award
Simantov Ronit
Director 3 500
Value: $0
Jun 17, 2022
Buy
Stock Option (Right to Buy)
A-Award
Raab Michael
Director 3 500
Value: $0
Jun 17, 2022
Buy
Stock Option (Right to Buy)
A-Award
Raab Michael
Director 3 500
Value: $0
Jun 17, 2022
Buy
Stock Option (Right to Buy)
A-Award
Simantov Ronit
Director 3 500
Value: $0
Jun 17, 2022
Buy
Stock Option (Right to Buy)
A-Award
Woiwode Thomas
Director
Director 3 500
Value: $7K
Jun 17, 2022
Buy
Stock Option (Right to Buy)
A-Award
Woiwode Thomas
Director 3 500
Value: $0
Jun 17, 2022
Buy
Stock Option (Right to Buy)
A-Award
Nichol Geoffrey
Director
Director 3 500
Value: $7K
Jun 17, 2022
Buy
Stock Option (Right to Buy)
A-Award
Nichol Geoffrey
Director 3 500
Value: $0
Jun 17, 2022
Buy
Stock Option (Right to Buy)
A-Award
Pellizzari Christine A
Director 3 500
Value: $0

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT TEMPEST THERAPEUTICS INC.
Tempest Therapeutics
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops T...
GOLDEN STAR
Ticker Change Signal Date
FOX
$50.81
2.22% Jul 27
UNFI
$49.05
3.63% Jul 27
BIIB
$202.19
0.376% Jul 24
TSCO
$30.32
1.48% Jul 23
S
SW
$43.71
5.17% Jul 23

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE